secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2022-07-21T23:59:59+00:00
Accession:  0001193125-22-199246
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silverback Therapeutics to merge with ARS Pharmaceuticals; focus on needle-free epinephrine nasal spray neffy
--------------------------------------------------------------------------------

- Silverback equity holders expected to own ~37%, ARS holders ~63% on fully-diluted basis.
- Combined company expected to have ~$265M cash at close; merger expected Q4 2022; ticker to change to 'SPRY'.
- Silverback to reduce workforce by ~73% by Sept 2, 2022; severance charges ~$13M cash + $2M non-cash.
- ARS preparing NDA submission for neffy in Q3 2022; potential US launch in 2023.
- Combined company CEO will be Rich Lowenthal (ARS); board of 10 members (7 from ARS, 3 from Silverback).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312522199246/0001193125-22-199246-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312522199246/d379554d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-199246

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer